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Introduction: Intravenous levetiracetam (LEV) is broadly used in the treatment of status 
epilepticus (SE). A loading dose is usually infused, aiming to reach quickly the range of 
plasma concentrations considered as therapeutic (12-46 mg/L). We evaluated the potential 
therapeutic interest of LEV plasma concentrations in patients with SE by comparing 
responders and non-responders. 
Material and Methods: Retrospective analysis of a SE registry, including patients since 
2015 with at least one available LEV plasma level measured less than 36 hours after loading. 
A Bayesian maximum likelihood approach based on a population pharmacokinetic model was 
used to estimate LEV exposure parameters. We compared plasma levels and 
pharmacokinetics parameter estimates between responders and non-responders. Therapeutic 
response was defined as SE cessation within 24 hours following LEV introduction.  
Results: Between February 2015 and April 2016, we included 29 patients (45 plasma levels). 
Variability was salient in LEV dosages administered and monitoring practice. There were no 
difference in median plasma concentrations (19.5 versus 21.5 mg/l; p=0.71), median 
estimated LEV exposure (25.8 versus 37.0 mg/l, p=0.58), peak (30.4 versus 41.5 mg/l, 
p=0.36) or residual levels after loading dose (14.4 versus 20.5 mg/l, p=0.07) between 
responders and non-responders.   
Conclusion: LEV exposure does not seem to significantly differ between responders and non-
responders. Loading doses of 30 mg/kg seem however appropriate to quickly reach the target 
exposure level. Variability in LEV dosing and monitoring precludes firm conclusions about 
concentration-response associations, which deserve further systematic investigation.  
Introduction 
Status epilepticus (SE) is a neurologic emergency (Trinka et al., 2015) that can lead to serious 
morbidity and mortality, especially when prolonged (Betjemann and Lowenstein, 2015) 
(https://www.ncbi.nlm.nih.gov/pubmed/28681418). Strong evidences support the use of 
benzodiazepines as first line treatment; the second line is based on weaker evidence, and 
typically consists of non-sedative antiepileptic drugs (AED) given intravenously. Three AEDs 
have been commonly prescribed since several years: phenytoin, valproate and levetiracetam 
(LEV) (Brophy et al., 2012; Glauser et al., 2016; Meierkord et al., 2010), while lacosamide is 
also increasingly used.  
 
LEV is a broad-spectrum AED available intravenously since 2007 in Switzerland, targeting 
the synaptic vesicle protein 2 (SV2a) (Deshpande and DeLorenzo, 2014). It is eliminated 
mostly through the renal route and has a low potential for drug to drug interaction, and 
induced sedation is mild (Trinka and Dobesberger, 2009); it is therefore one of the most 
widely prescribed AED in SE (Brigo et al., 2016) and its use seems to be increasing 
(https://link.springer.com/article/10.1007%2Fs40263-017-0424-1). 
 
The objective regarding the use of a loading dose is to reach without delay the reference 
plasma level interval, which for LEV is reported between 12 and 46 mg/l in chronic epilepsy 
patients (Patsalos et al., 2008). The ideal LEV loading dose is not established: in consecutive 
guidelines, there is a trend toward increasing doses (table 1). Maintenance LEV dosage 
should then keep circulating concentrations between those boundaries. In our centre, loading 
dose of 30 mg/kg is recommended. Estimated drug exposure through LEV plasma 
concentrations may help to validate a rational loading dose able to produce the desired 
exposure.  
Our study aimed at evaluating the current use of LEV in SE, and at clarifying the potential 
therapeutic interest of LEV plasma concentrations in acute SE management. In particular, we 
looked for an association between plasma levels and achievement of therapeutic response. 
 
Materials and Methods 
This is a retrospective analysis of our previously described prospective SE registry (Novy et 
al., 2010), which is approved by our institutional review board and includes all consecutive 
adult patients with SE treated at the CHUV (Lausanne University Hospital). Inclusion is 
performed by two epileptologists (JN and AOR) based on clinical evaluation and EEG (the 
latter being mandatory for nonconvulsive episodes).  SE is defined as a single seizure lasting 
more than 5 minutes, or shorter consecutives seizures without complete recovery between the 
episodes. Episodes occurring in patients younger than 16 years old or post-cardiac arrest are 
excluded because of important differences in prognosis. Resolution of SE was determined as 
the moment of seizure cessation, as demonstrated by clinical examination and subsequently 
confirmed by EEG documentation, usually obtained within 24 hours.  
 
For every episode, detailed patients demographics and body weight were prospectively 
collected, together with SE duration and clinical characteristics, including presence of a 
potentially fatal aetiology, as defined previously (Rossetti et al., 2006). The Status Epilepticus 
Severity Score (STESS), a validated composite prognosis score based on four items (age, 
consciousness before treatment, worst seizure type and previous history of seizure (Rossetti et 
al., 2008), was calculated on admission. The exact sequences of administration of LEV and 
other AEDs, with loading and maintenance doses including timing of injections, were also 
prospectively recorded. The loading dose was defined as a single or serial LEV 
administrations given at close intervals (less than 4 hours) with the aim of reaching 
therapeutic concentrations. For the purpose of this study, therapeutic response to LEV was 
assumed if LEV was the last AED introduced in the 24 hours before SE resolution. The 
interval between LEV loading and response (either end of SE for responders, or introduction 
of another AED for non-responders) was defined as the observation period. 
 
We screened all patients having received LEV for SE between February 2015 (when this test 
became available in our laboratory) and April 2016, including those with LEV plasma levels 
collected during 36 hours after the loading dose, defined as the first dose of the initiated 
treatment. Further LEV plasma levels were collected if they were sampled within 7 days 
following SE onset, and used to adjust an individual LEV pharmacokinetic model.  All data 
concerning dosage regimen, time of blood sampling, serum creatinine, ammonium and 
comedications was retrospectively collected. Levels were determined using ultra-performance 
liquid chromatography with tandem mass spectrometry (Decosterd et al., 2015). In case of 
recurrent SE episodes in a single patient, only the first episode was included in the analysis. 
To evaluate a potential inclusion bias, we compared this study cohort with the other patients 
concomitantly treated with LEV in our centre (also prospectively included in the registry), in 
whom no LEV plasma levels were available.  
 
LEV plasma concentration values were interpreted based on a population pharmacokinetic 
model (Pigeolet et al., 2008), describing LEV disposition by a one-compartment open model 
with first order elimination and additive residual error. According to this model, LEV 
apparent clearance is affected by various covariates retrieved in each patient (body weight, 
gender, creatinine, clearance and concomitant intake of enzyme inducers or inhibitors). 
Similarly, LEV distribution volume depends on bodyweight, disease, and comedication with 
valproic acid. Using this model, a Bayesaian maximum-likelihood approach was applied to 
the available sparse samples, and a posteriori parameters were determined for each patient and 
used to estimate individual LEV exposure. The pharmacokinetic analysis was performed 
using the NONMEM program (version 7.3), running with Pirana (2.9.3) and PSN-toolkit 
(4.2)(Keizer et al., 2011). 
 
LEV exposure was assessed with two parameters: plasma level measured within 36 hours 
(obtained from the laboratoy files) and mean concentration during the exposure period 
(derived from the individualized pharmacokinetic model as the area under concentration 
curve divided by the duration of the observation period). In addition, peak and trough LEV 
concentrations were extrapolated based on the same model, and defined as the maximal and 
minimal concentrations reached between the loading and the first maintenance dose. 
 
For statistical analysis, patients were divided according to their therapeutic response to LEV. 
We compared LEV exposure between both groups using a Mann-Whitney U-test.  Both 
groups were further compared for other available clinical characteristics using Chi-Square, 
Fisher, Mann-Whitney U and Spearman tests, as required. Secondarily, data were adjusted 
(sequentially using one corrector each time given the sample size) for predictors of outcome, 
such as position of LEV in the treatment, STESS, and potentially fatal SE aetiology (Novy et 
al., 2010; Sutter et al., 2013), in a binary logistic regression. Calculations were done with 
SPSS version 23.0 (IBM corp., Armonk, NY). 
 
Results 
Between February 2015 and April 2016, 81 patients with SE were treated with at least a 
loading dose of LEV in our centre. We identified 29 (36%) patients with available plasma 
levels, among whom 23 (79%) were newly treated by levetiracetam. These 29 patients are the 
object of this analysis. 
 
As an internal validity assessment, the 29 included patients were comparable to the 52 other 
patients receiving LEV during the same period, but without plasma level measurement, 
regarding therapeutic response (34% versus 29%; p=0.6, χ 2), potentially fatal etiologies 
(57% versus 62%, p=0.7, χ 2), mortality at discharge (10% versus 20%, p=0.4, Fisher test), 
favourable STESS of <3 (24% versus 21%, p=0.8, χ 2), total number of AEDs used (median:  
3 versus 3, p=0.96, U test) and position of LEV within the treatment sequence (median: 2th  
versus 2th, p=0.2, U test). 
 
Among the included patients, a therapeutic response to LEV was observed in 10 (35%).  
Detailed demographics, clinical and treatment characteristics comparing responders and non-
responders are given in table 2. There was no significant difference between both groups. 
LEV loading doses varied between 1000 and 3000 mg, with a median of 2000 mg, 
representing 27.8 mg/kg body weight with a range of 17.2 to 38.5 mg/kg. This loading dose 
tended to be somewhat lower in responders, while non-responders received a higher 
cumulated LEV doses essentially because of the SE longer duration. We did not record any 
side effects directly related to LEV treatment.  
 
Overall, 46 plasma levels were available, among which 29 were collected within 36 hours. 
The majority (82%) were above the lower reference limit of 12 mg/l. Plasma levels were 
measured most frequently after one loading dose plus one maintenance dose (n=13; 45%). 
Only 2 patients (8%) had a plasma level obtained just after a loading dose. According to usual 
recommendations, pharmacokinetic steady state is reached only after at least 4 identical doses, 
this constellation corresponded only to 11 plasma levels (25%) in 9 patients (31%). Median 
time between loading dose and the first considered plasma level was 17 hours (range 7-37h). 
Finally, the time between last dose and blood sampling appeared highly variable, with a 
median of 8.5 h (range 0.9-15.3 h). 
 
The measured plasma levels did not correlate with the corresponding loading doses (p=0.85, 
Spearman) or loading doses adjusted to bodyweight (p=0.12, Spearman) (figure 1), even 
when considering only plasma levels obtained before 36 hours (p=0.81 for loading dose; 
p=0.96 for loading dose related to body weight, Spearman). Conversely, mean plasma levels 
derived from the pharmacokinetic model during the observation presented the expected, 
correlation with LEV loading doses (p<0.001, Spearman). Collected and calculated plasma 
levels are displayed in table 3.  
 
No difference in LEV exposure was observed between responders and non-responders, for 
both the plasma levels measured before 36 hours (p=0.71, U test) and the calculated mean, 
peak and trough plasma levels (p=0.61, 0.36 and 0.37 respectively, U test). There was a trend 
toward higher plasma concentration at the time of response determination in non-responders 
(25.4 versus 36.0, p=0.07, U test).  
 
Adjusting the measured plasma levels after loading dose for LEV position in the treatment 
sequence (odd-ratio OR: 0.98; 95% confidence interval CI: 0.91-1.07; p=0.73), potentially 
fatal etiology (OR: 1.01; CI: 0.93-1.009; p=0.9), or STESS (OR: 1.004; CI: 0.93.1.08; 
p=0.92) did not reveal any difference. Similarly, calculated mean LEV plasma levels did not 
show any association with clinical response after adjustment for position of LEV in the 
treatment (OR: 0.93; CI: 0.85-1.02; p=0.14); fatal etiology (OR: 0.97; CI: 0.90-1.04; p=0.41), 
and STESS (OR: 0.98; CI: 0.92-1.05; p=0.53). 
 
To assess the ideal loading dose, a peak level of 40 mg/L was targeted, considering the upper 
limit of the reference range. According to model-based extrapolations of peak concentrations, 
a loading dose of 30 mg/kg seemed optimal to reach this target in most patients (figure 3). 
Maintenance doses can be started 12h later, in line with the biological half-life of LEV 
(estimated between 7.7 and 12.4 h in our patients). The maintenance dosage should then be 
adapted based on renal function. 
 
Discussion 
The lack of correlation observed between measured plasma levels and loading doses seems 
due to highly variable sampling times after loading injection. The rather short LEV plasma 
half-life (suggested to be even shorter in critical setting, Spencer) explains the marked 
confounding effect of this variability. Measuring LEV plasma levels in this clinical setting 
seems thus of little value beyond merely ascertaining that the patient has received the drug. 
LEV exposure would be more properly assessed through a standardised protocol with 
consistent intervals between the administration of loadings doses and the collection of blood 
samples. 
 
To overcome the limitations of our direct plasma measurements, we further characterised 
LEV exposure in the patients using a pharmacokinetic model previously validated in 
Caucasian subjects (Pigeolet et al., 2008). This calculation integrated influential covariables 
and estimated maximum likelihood LEV exposure in each patient, assumed to represent a 
more robust indicator of LEV activity (Spencer et al., 2011). The number of patients and 
blood levels precluded the elaboration of a proper population model. This approach 
adequately correlated the loading dose with the estimated peak plasma level, but failed to 
identify any difference in LEV exposure between responders and non-responders. Several 
considerations might explain this finding.  
 
Firstly, the spread of LEV exposure levels was relatively limited in our study, thus precluding 
the observation of markedly underdosed or overdosed patients. Secondly, the reference 
therapeutic plasma interval of 12-46 mg/l has been established in patients having chronic 
epilepsy, but not in SE, which might necessitate different and possibly higher levels, as 
suggested e.g. for topiramate (Wyllie et al., 2011). Thirdly, blood and brain compartments 
display different pharmacokinetic properties regarding LEV: animal studies (Doheny et al., 
1999; Nicolas et al., 2016) showed indeed a mismatch between plasma and central nervous 
system levels. LEV elimination from the central compartment is probably slower than from 
circulation, thus explaining LEV sustained efficacy when given twice daily in spite of the 
relatively short half-life (Perucca and Johannessen, 2003). Plasma levels may thus be of 
limited help to predict the availability of treatment at its biological target. Fourthly, the 
relationship between blood or brain exposure and therapeutic efficacy might display 
important between-patient pharmacodynamic variability: a similar observation was done for 
lacosamide in the same clinical setting (Perrenoud et al., 2017). Making a parallel with 
chronic epilepsy in an outpatient setting, most of the medication effect in responders is 
usually obtained at low dosage, and increasing doses seem to bring little additional benefit in 
terms of remission (D’Anto et al., 2017; Poolos et al., 2017) 
 
Our response rate to LEV was 34%, lower than previous studies with similar dosages that 
reported rates of 68.5% in 204 episodes (Yasiry and Shorvon, 2014), or 65.4% in 156 
episodes (Trinka and Dobesberger, 2009). Direct comparisons are however difficult, because 
the definition of clinical response was not uniform across those studies and most of them, as 
ours, had a retrospective design making them prone to inclusion bias. Our response rate 
appears congruent with a previous study in our centre reporting a response rate of 51.7% in 58 
episodes (Alvarez et al., 2011). In that study, LEV was given as a second line treatment, 
which is also the case for 22 (76%) of our patients, and the definition of response did not 
include the 24h criterion, thus potentially leading to a higher rate.  
 
Our study has limitations. Firstly, our response definition represents a simplification of the 
complex factors determining SE cessation, and does not consider the potential effects of 
agents previously introduced. It represents however a pragmatic and objective endpoint from 
a clinical view (Redecker et al., 2017). Secondly, the retrospective design and relatively 
limited number of patients prevents drawing any firm conclusions: e.g. the “ideal” loading 
dose of LEV found to be 30 mg/kg deserves confirmation in a prospective trial. The 
evaluation of concentration-response relationships in our 29 cases was statistically powered to 
find only strong associations. In addition, our estimation of LEV exposure derived from 
Bayesian fitting of a population pharmacokinetic model is probably less accurate than would 
have been direct peak and trough measurements. Conclusions regarding less prevalent 
outcomes (e.g. mortality) or more complex analyses (e.g. multivariate logistic regression) are 
limited by the number of cases. Adverse events ascertainment suffers from the retrospective 
assessment. Thirdly, the loading doses oriented around our local guidelines recommending 30 
mg/kg prevented tests with as much as 60 mg/kg recommended by some newer guidelines 
(Glauser et al., 2016). Further studies might clarify whether a dose-dependency of LEV 
efficacy would be revealed at those higher levels. The strength of the study is the prospective 
collection of clinical data in a registry having a robust internal validity (being run by the same 
investigators since several years), the detailed information regarding LEV doses, and the 
integration of LEV plasma concentrations in a validated pharmacokinetic model to overcome 
the bias resulting from variability in plasma sampling.  
 
In conclusion, we identified no clear association between LEV exposure and therapeutic 
response of SE patients after LEV loading doses, even using a population pharmacokinetic 
approach to compensate the variability in LEV dosing and plasma sampling. These findings 
leave open the question of the usefulness of therapeutic plasma concentration monitoring of 
LEV in SE, in analogy with LCM. For further studies and general clinical practice, a 
standardised protocol for plasma level sampling applying consistent timing from last dosing, 
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Figure 1: Measured plasma levels and loading dose related to body weight. Dotted lines 
represent the reference range of 12-46-mg/l containing 37 (82%) of measured plasma levels, 
with 4 (9%) below and 1 (3%) above it.  No correlation between plasma levels and loading 








Figure 2a and 2b: Correlation between calculated mean LEV concentration and loading dose 







Figure 3: Distribution of the 29 peak plasma levels estimated by Bayesian maximum 





Guidelines and reference Year Recommended 
doses 
Equivalent relative to 
body weight (70kg) 
European Federation of 
Neurological Society 
(EFNS) (Meierkord et al., 
2010) 
2010 1000-3000mg 14-42 mg/kg 
Neurocritical Care Society 
(NCS) (Brophy et al., 
2012) 
2010 1000-3000mg 14-42 mg/kg 
American Epilepsy Society 
(AES) (Glauser et al., 
2016) 
2016 - 60mg/kg 
 
Table 1: Comparison of the recommended LEV loading dose from 3 SE guidelines according 













p-value Test used 
Age - years 
Median (range) 
 
73 (47-89) 75 (47-89) 73 (59-78) 0.43 U 
Gender - males 
n (%) 
13 (45%) 3 (30%) 10 (53%) 0.43 Fisher 
Potentially fatal cause 
n (%) 
16 (57%) 3 (30%) 13 (68%) 0.11 Fisher 
Mortality at hospital 
discharge - 
N (%) 
3 (10%) 2 (20%) 1 (5%) 0.27 Fisher 
Favourable STESS of 
<3 – n (%) 
7 (24%) 1 (10%) 6 (32%) 0.37 Fisher 
SE duration before 
LEV - hours 
Median (range) 
3.5 (0-1-99) 3.6 (0.1-42) 
 
3.2 (0.5-99) 0.73 U 
SE duration 
after LEV loading - 














2.5   
(0.3-50.8) 
0.78 U 
Total number of 
AEDs used 
Median (range) 
3 (2-7) 2 (2-3) 4 (2-7) <0.001 U 
Previous LEV 
treatment 
6 (21%) 2 (20%) 4 (13%) 0.67 Fisher 
Position of LEV in the 
treatment sequence 
Median (range) 
2 (1-3) 2 (2-3) 2(1-3) 0.12 U 
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Table 2: Clinical characteristics of patients according to LEV response. Comparison between 
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Table 3:  
Characteristics regarding measured plasma levels and calculated LEV mean, peak and trough 
plasma level from the population pharmacokinetic model. Note that direct comparison of the 
45 overall plasma levels between responders and non-responders is not applicable because the 
number of patients (n) is lower than the number of plasma levels.  
 
 
 
 
 
